Where does LivaNova USA, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), LivaNova USA, Inc. ranks #4,421 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does LivaNova USA, Inc. hold?

LivaNova USA, Inc. holds 80 US utility patents granted between 2019 and 2025, spanning 7 technology areas.

What is LivaNova USA, Inc.'s Innovation Score?

LivaNova USA, Inc. has an Innovation Score of 41.8 out of 100 (top 32% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does LivaNova USA, Inc. focus on?

LivaNova USA, Inc.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 69 patents, ranking #49 of 1,943 assignees active in that subclass. Grants appear in 7 CPC subclasses total.

Is LivaNova USA, Inc.'s patent grant rate increasing or decreasing?

LivaNova USA, Inc.'s recent grant velocity is +293% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for LivaNova USA, Inc.'s patents?

LivaNova USA, Inc.'s patents average 19.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the LivaNova USA, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

LivaNova USA, Inc.

USPTO PatentsView assignee record - 80 granted patents across 7 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Livanova ranks #4,421 of 49,997 tracked US assignees by granted-patent volume, with 80 patents across 7 technology areas.

#4,421
of 49,997 US assignees by volume: Top 32%
by Innovation Score (41.8/100): 19.9
avg claims per patent: +293%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4421 · US Corporation #4,421 · 80 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 80 grants
TOP-DECILE #4,421/49,997
PHOTO-FINISH Draka Comteq B V
CPC-NARROW A61N · 7 areas
INNOV-PAR 41.8/100
CLAIMS-RICH 19.9 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +293% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Draka Comteq B.V. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Livanova’s 41.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 15.2 pts (36%) Velocity 5.4 pts (13%) Breadth 9.4 pts (22%) Claim depth 11.9 pts (28%)

Qualcomm Incorporated · highest

85
BD Kiestra B V · near

42
Elekta AB (publ) · near

42
F Hoffmann-La Roche · near

42
Hyperconnect · near

42
LivaNova USA · this assignee

42
3D Lighting… · lowest

7

What this shows Livanova's Innovation Score is 41.8/100 (top 32% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Livanova?

Each dot is one of Livanova’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Livanova’s own 19.9 claims/patent is ABOVE the 8.0 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Livanova vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Livanova's grants concentrate

LivaNova USA, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 86.3% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2021 (16 grants) versus a trough of 9 in 2022. By volume, Livanova sits between Dupont Safety & Construction, Inc. and Nippon Hoso Kyokai.

Livanova's three-year grant acceleration

From 2019–2021 to 2022–2024, LivaNova USA, Inc. moved from 41 to 33 grants (0.81x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Dupont Safety & C…

80
Draka Comteq B V

80
EIS

80
IGT Canada Soluti…

80
Medicaroid

80
Mitac Computing T…

80
Nihon Plast

80
Nippon Hoso Kyokai

80
Livanova USA ◀

80

What this shows LivaNova holds 80 patents at rank #4,421, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near LivaNova

By rank, the assignees closest to #4,421 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in LivaNova's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for LivaNova, neither rank-band nor same-CPC leaders (those blocks stay above). In A61N (Electrotherapy), LivaNova ranks #49 of 1,943 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (42 here).

Elekta AB (publ) 42 Hyperconnect LLC 42 F. Hoffmann-La Roche AG 42 BD Kiestra B.V. 42

Similar claim depth

Nearest assignees by average claims per patent (19.9 here).

SRI International 19.9 avg NetApp, Inc. 19.9 avg Willis Electric Co., Ltd. 19.9 avg Seattle Genetics, Inc. 19.9 avg

Livanova's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 32% higher than 68% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

LivaNova USA, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	15	18.8%
2020	10	12.5%
2021	16	20.0%
2022	9	11.3%
2023	13	16.3%
2024	11	13.8%
2025partial year	6	7.5%

Which technologies does LivaNova USA, Inc. patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 69

A61B - DIAGNOSIS; SURGERY; Identification 48

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 18

G16Z - Information AND Communication Technology [ICT] Specially Adapted FOR Specific Application Fields, NOT Otherwise Provided FOR 5

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 2

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 1

Top 7 of 7 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

LivaNova USA, Inc.'s patent record in context - here's where to go next.

LivaNova USA, Inc.'s lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 86.3% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #4,421 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare LivaNova USA, Inc. against Dupont Safety & Construction, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.